Skip to main content
Retour
ILMN logo

Illumina, Inc.

Qualité des données : 100%
ILMN
NASDAQ Healthcare Medical - Diagnostics & Research
126,20 €
▲ 0,22 € (0,17%)
Cap. Boursière : 19,30B
Fourchette du Jour
122,46 € 128,74 €
Fourchette 52 Semaines
68,70 € 155,53 €
Volume
1 405 781
Moyenne 50J / 200J
131,49 € / 113,06 €
Clôture Précédente
125,98 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (631 pairs)

Métrique Action Médiane du Secteur
P/E 22,7 0,2
P/B 7,1 3,0
ROE % 33,4 3,6
Net Margin % 19,6 3,8
Rev Growth 5Y % -1,0 10,0
D/E 0,9 0,2

Objectif de Cours des Analystes

Hold
147,13 € +16.6%
Low: 110,00 € High: 170,00 €
P/E Prévisionnel
24,60
BPA Prévisionnel
5,13 €
Croissance BPA (est.)
+0,0%
CA Est.
4,54B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 8,23 €
8,07 € – 8,36 €
5,68B 2
FY2029 7,53 €
7,39 € – 7,65 €
5,40B 2
FY2028 6,65 €
6,24 € – 7,60 €
5,09B 6

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-05 1,24 € 1,35 € +8,9%
2025-10-30 1,17 € 1,34 € +14,5%
2025-07-31 1,02 € 1,19 € +16,7%
2025-05-08 0,94 € 0,97 € +3,2%
2025-02-06 0,92 € 0,86 € -6,5%
2024-11-04 0,88 € 1,14 € +29,7%
2024-08-06 0,11 € 0,36 € +228,5%
2024-05-02 0,04 € 0,09 € +106,4%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Revenue declined -1,03% annually over 5 years
ROE of 33,36% indicates high profitability
Net margin of 19,58% shows strong profitability
Generating 931,00M in free cash flow
Cash machine — converts 109,53% of earnings into free cash flow
Capital efficient — spends only 3,41% of revenue on capex

Croissance

Revenue Growth (5Y)
-1,03%
Revenue (1Y)-0,69%
Earnings (1Y)N/A
FCF Growth (3Y)81,70%

Qualité

Return on Equity
33,36%
ROIC12,30%
Net Margin19,58%
Op. Margin19,92%

Sécurité

Debt / Equity
0,94
Current Ratio2,08
Interest Coverage8,65

Valorisation

P/E Ratio
22,70
Forward P/E24,60
P/B Ratio7,09
EV/EBITDA23,62
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -0,69% Revenue Growth (3Y) -1,81%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -1,03% Earnings Growth (5Y) 2,77%
Profitability
Revenue (TTM) 4,34B Net Income (TTM) 850,00M
ROE 33,36% ROA 12,79%
Gross Margin 66,49% Operating Margin 19,92%
Net Margin 19,58% Free Cash Flow (TTM) 931,00M
ROIC 12,30% FCF Growth (3Y) 81,70%
Safety
Debt / Equity 0,94 Current Ratio 2,08
Interest Coverage 8,65
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 22,70 Forward P/E 24,60
P/B Ratio 7,09 P/S Ratio 4,44
PEG Ratio -0,14 Forward PEG N/A
EV/EBITDA 23,62 Fwd EV/EBITDA N/A
Forward P/S 4,25 Fwd Earnings Yield 4,07%
FCF Yield 4,82%
Market Cap 19,30B Enterprise Value 20,43B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4,34B 4,37B 4,50B 4,58B 4,53B
Net Income 850,00M -1,22B -1,16B -4,40B 762,00M
EPS (Diluted) 5,44 -7,69 -7,35 -28,05 5,05
Gross Profit 2,89B 2,86B 2,74B 2,97B 3,15B
Operating Income 865,00M -833,00M -1,07B -4,18B -123,00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 6,64B 6,30B 10,11B 12,25B 15,22B
Total Liabilities 3,92B 3,93B 4,37B 5,65B 4,48B
Shareholders' Equity 2,72B 2,37B 5,75B 6,60B 10,74B
Total Debt 2,55B 2,62B 2,26B 3,56B 2,54B
Cash & Equivalents 1,42B 1,13B 1,05B 2,01B 1,23B
Current Assets 3,29B 2,75B 2,61B 3,56B 2,71B
Current Liabilities 1,59B 1,55B 1,57B 2,77B 1,09B